Italian University Study Confirms E-Cigarettes' Effectiveness for Smoking Cessation

Dec.05.2024
Italian University Study Confirms E-Cigarettes' Effectiveness for Smoking Cessation
A recent evaluation by a research team from an Italian university shows that e-cigarettes are more effective than other methods in helping people quit smoking. The study notes that, although the long-term success rate of e-cigarettes is only 10%-12%, their potential warrants further research and integration into public health policies.

According to Catania Today's report on December 5th, a recent assessment conducted by the CoEHAR research team at the University of Catania showed that e-cigarettes are more effective than other methods in helping people quit smoking.

 

The study was published in the journal Drug and Alcohol Dependence, evaluating 16 systematic reviews covering data from 24 randomized controlled trials (RCTs).

 

"We believe the data from our review can support the integration of harm reduction strategies into public health policies in many countries," said Renée O'Leary, the first author of the review. 

 

"However, the review also highlights a critical gap in existing cessation strategies, with long-term success rates for e-cigarettes still modest, at 10%-12%, and insufficient research on relapse rates. New treatments and innovative approaches are needed."

 

Riccardo Polosa, co-author of the study and founder of CoEHAR, added: "This study provides solid evidence supporting the potential of modified-risk devices as an effective tool for smoking cessation, but it also calls attention to the need for better clinical guidelines and further analysis of long-term outcomes."

 

Riccardo Polosa, co-author of the study and founder of CoEHAR, added: "This study provides solid evidence supporting the potential of modified-risk devices as an effective tool for smoking cessation, but it also calls attention to the need for better clinical guidelines and further analysis of long-term outcomes."

 

We welcome news tips, article submissions, interview requests, or comments on this piece.

Please contact us at info@2firsts.com, or reach out to Alan Zhao, CEO of 2Firsts, on LinkedIn


Notice

1.  This article is intended solely for professional research purposes related to industry, technology, and policy. Any references to brands or products are made purely for objective description and do not constitute any form of endorsement, recommendation, or promotion by 2Firsts.

2.  The use of nicotine-containing products — including, but not limited to, cigarettes, e-cigarettes, nicotine pouchand heated tobacco products — carries significant health risks. Users are responsible for complying with all applicable laws and regulations in their respective jurisdictions.

3.  This article is not intended to serve as the basis for any investment decisions or financial advice. 2Firsts assumes no direct or indirect liability for any inaccuracies or errors in the content.

4.  Access to this article is strictly prohibited for individuals below the legal age in their jurisdiction.

 

Copyright

 

This article is either an original work created by 2Firsts or a reproduction from third-party sources with proper attribution. All copyrights and usage rights belong to 2Firsts or the original content provider. Unauthorized reproduction, distribution, or any other form of unauthorized use by any individual or organization is strictly prohibited. Violators will be held legally accountable.

For copyright-related inquiries, please contact: info@2firsts.com

 

AI Assistance Disclaimer

 

This article may have been enhanced using AI tools to improve translation and editorial efficiency. However, due to technical limitations, inaccuracies may occur. Readers are encouraged to refer to the cited sources for the most accurate information.

We welcome any corrections or feedback. Please contact us at: info@2firsts.com

NJOY and Altria ask federal court to halt ITC proceeding, alleging multiple constitutional defects
NJOY and Altria ask federal court to halt ITC proceeding, alleging multiple constitutional defects
A filing in the U.S. District Court for the Eastern District of Virginia (Richmond Division) shows NJOY and Altria entities submitted a plaintiffs’ reply supporting their motion for summary judgment, arguing the challenged ITC proceeding is unconstitutional on multiple grounds, including ALJ appointment authority, removal protections, and Article III limits under the Jarkesy framework. The plaintiffs seek summary judgment and a permanent injunction barring continuation of the ITC proceeding.
Jan.08 by 2FIRSTS.ai
Altria Reports Full-Year 2025 Results: Revenue Down 3.1%, Cigarette Volumes Slide 10% as NJOY Takes Impairment Hit
Altria Reports Full-Year 2025 Results: Revenue Down 3.1%, Cigarette Volumes Slide 10% as NJOY Takes Impairment Hit
Altria has released its full-year 2025 results, reporting full-year net revenues of $23.279 billion, down 3.1% year over year. Domestic cigarette shipment volume fell 10% for the year. on! nicotine pouches reached a 7.7% share of the U.S. oral tobacco category in the fourth quarter. NJOY posted $21 million in net revenues in Q4, while full-year net revenues were negative $13 million (mainly due to returns and related factors).
Jan.30 by 2FIRSTS.ai
Kumulus Vape launches Labster production unit for e-liquids and DIY concentrates
Kumulus Vape launches Labster production unit for e-liquids and DIY concentrates
Kumulus Vape has launched Labster, a 700 sq m production unit in the Lyon Metropolis near the group’s headquarters, for e-liquids and DIY concentrates. The site is equipped with automated lines supplied by CDA (Constructions d’Automatismes) to carry out bottling and labeling. Its theoretical capacity is described as several million bottles per year in 10–100 ml formats, and it is already operational.
Feb.06 by 2FIRSTS.ai
Qnovia’s Heat-Free Inhalable Nicotine Replacement Therapy Posts Positive First-in-Human Data, Advances FDA and MHRA Filings as Funding Expands
Qnovia’s Heat-Free Inhalable Nicotine Replacement Therapy Posts Positive First-in-Human Data, Advances FDA and MHRA Filings as Funding Expands
U.S.-based medical startup Qnovia Inc. reported positive results from its first-in-human clinical trial of RespiRx, an inhalable nicotine replacement therapy (NRT) device designed to support smoking cessation.
Innovation
Feb.24
Cambodian's Phnom Penh Military Police continue crackdown after 300,000-device raid
Cambodian's Phnom Penh Military Police continue crackdown after 300,000-device raid
Phnom Penh Military Police said they have continued cracking down on locations selling electronic devices used for smoking chemicals, following a major raid last week that confiscated 300,000 electronic smoking devices.
Jan.20 by 2FIRSTS.ai
Product | “Switch”-Style Design, Rated 30,000 Puffs: Open-System Klip’s Switch Edition Listed on French Channels
Product | “Switch”-Style Design, Rated 30,000 Puffs: Open-System Klip’s Switch Edition Listed on French Channels
The open-system e-cigarette Klip’s Switch Edition 30K has recently been listed on multiple French vape e-commerce channels. Channel information indicates the product is a collaboration between Fumytech and Tornadoliq and uses an open refill solution. The kit includes a 7 mL pod/cartridge and two 10 mL refill bottles, with a claimed total usage of around 30,000 puffs. The mainstream retail price is about €19.90.
Feb.06 by 2FIRSTS.ai